China Biologic Reiterates Full Year 2018 Financial Forecast

BEIJING,Jan. 7,2019 --China Biologic Products Holdings,Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"),a leading fully integrated plasma-based biopharmaceutical company in China,today reiterated its previously revised full year 2018 forecast.

Full year 2018 non-GAAP adjusted income from operations is expected to increase in the range of 0% to 2% in RMB terms and non-GAAP adjusted net income is expected to decrease by 2% to 4% in RMB terms over full year 2017 financial results.

Excluding TianXinFu,full year 2018 non-GAAP adjusted income from operations is expected to decrease by 16% to 18% in RMB terms and non-GAAP adjusted net income to decrease by 19% to 21% in RMB terms over full year 2017 financial results.

This guidance does not factor in any potential foreign currency translation impact. Having previously adopted an exchange rate of approximately RMB6.76 = $1.00 based on weighted average quarterly exchange rates in 2017 in translating 2017 financial results,the Company expects that the non-GAAP adjusted income from operations and non-GAAP adjusted net income in USD terms in 2018 will be affected by the foreign currency translation impact.

This forecast reflects the Company's current and preliminary views,which are subject to change.

About China Biologic Products Holdings,Inc.

China Biologic Products Holdings,Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary,Shandong Taibang Biological Products Co.,Ltd. and its wholly owned subsidiary,Guizhou Taibang Biological Products Co.,Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co.,Ltd. The Company sells its products to hospitals,distributors and other healthcare facilities in China. For additional information,please see the Company's website www.chinabiologic.com.

Non-GAAP Disclosure

This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options and restricted shares granted to employees and directors under the Company's 2008 Equity Incentive Plan,amortization of acquired intangible assets and land use rights,and an income tax benefit related to U.S. Tax Reform. The Company's management believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies. A reconciliation of GAAP income and GAAP net income,on the one hand,and non-GAAP adjusted income and non-GAAP adjusted net income,on the other hand,for the full year 2018,will be provided when the Company announces its complete financial results for the fourth quarter and full year ended December 31,2018.

In addition,as the Company evaluates certain key items of its financial results on a local currency basis (i.e.,in RMB) in addition to the reporting currency (i.e.,in USD),this news release contains local currency information that eliminates the impact of fluctuations in foreign currency exchange rates. The Company believes that,given its operations primarily based inChina,providing local currency information on such key items enhances the understanding of its financial results and evaluation of performance in comparison to prior periods. Changes in local currency percentages are calculated by comparing financial results denominated in RMB from period to period.

Safe Harbor Statement

This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products Holdings,Inc. and its subsidiaries. All statements,other than statements of historical fact included herein,are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "intend," "believe," "expect," "are expected to," "will," or similar expressions,and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable,they involve assumptions,risks,and uncertainties,and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements,which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors,including,without limitation,the risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws,the Company does not assume a duty to update these forward-looking statements.

Contact:

China Biologic Products Holdings,Inc.

Mr. Ming Yin

Senior Vice President

Phone: +86-10-6598-3099

Email: ir@chinabiologic.com

The Foote Group

Mr. Philip Lisio

Phone: +86-135-0116-6560

Email: phil@thefootegroup.com

View original content:/news-releases/china-biologic-reiterates-full-year-2018-financial-forecast-300773619.html